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ABSTRACT 
PURPOSE 
Oncotype DX, a gene expression assay widely employed to aid decision-making on 
adjuvant chemotherapy use in patients with primary oestrogen receptor-positive (ER+) 
breast cancer produces a Recurrence Score (RS) related to distant disease recurrence 
(DR) risk (RS%). In node-negative patients, RS can be integrated with 
clinicopathological parameters to derive RS-pathology-clinical (RSPC) that improves 
prognostic accuracy. 
METHODS 
Data were collected on patients having clinically indicated tests with an intermediate 
clinical risk of distant recurrence, and for whom the decision to prescribe 
chemotherapy remained unclear. Correlation between RS% and RSPC scores was 
examined. An agreement table was constructed using risk-categorised data. 
Association between RS%-derived categorical risk assignments and treatment 
recommendation was evaluated. 
RESULTS 
Data on 171 tests (168 patients) were available. Median DR risk by RS% was 11% 
(range, 3%-34%), by RSPC it was 15% (range, 4%-63%). Correlation between RS% and 
RSPC was 0.702 (p<0.001). RS% classified 57.3% of cases as low-, 32.2% intermediate-, 
Discordance between RS and RSPC for predicting risk of recurrence 
RS RSPC discordance DODSON et al 20170802.docx 4 
and 10.5% high-risk for DR; by RSPC proportions were 33.9%, 35.7%, and 30.4%, 
respectively. 
The number of patients receiving chemotherapy recommendations was: 14/87 (16.1%) 
categorised as low-risk by RS%, 27/49 (55.1%) as intermediate-risk and 12/13 (92.3 %) 
as high-risk. Of 149 patients recommended for endocrine treatment alone 28 (18.8%) 
were categorized by RS% as low-risk but by RSPC as intermediate- or high-risk. 
CONCLUSIONS 
In this group of patients RSPC assessed fewer patients as low-risk and more as high-risk 
than did RS%. The discordances between the scores indicate that RSPC estimates of 
risk should be considered when selecting patients for endocrine therapy alone. 
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INTRODUCTION 
Breast cancer is the most commonly diagnosed invasive cancer in women worldwide. 
Its incidence rate varies from 19 per 100,000 women in Eastern Africa to 90 per 
100,000 women in Western Europe [1]. In the UK, it currently represents 31% of all 
new female cancers, there were more than 55,000 newly reported cases in 2015. 
Incidence is rising and in developed countries is predicted to continue to rise by 2% per 
year for at least the next two decades [2]. 
In contrast breast cancer-specific mortality has fallen dramatically over the past 30-
years, with the 10-year survival rate for England and Wales currently standing at 
around 79%, which greatly improves on the figure of 49% for the early-1980’s [3]; 
reduced mortality rates are probably due to a combination of earlier detection and 
improved treatments. In particular, this improvement can be attributed to the 
introduction of post-surgical (adjuvant) drug treatments, which have made a huge 
impact in the treatment of oestrogen receptor-positive (ER+) breast cancer to the 
extent that more than 85% of women can expect to remain cancer-free 10-years after 
their initial diagnosis and treatment. However, it is now clear that, while all such 
women merit endocrine treatment, not all require additional chemotherapy to prevent 
recurrence of their disease following surgery. Clinical and pathological parameters 
carry much information about residual risk of distant disease recurrence (DR), and use 
of these in systematically produced, evidence-based risk indicators such as the 
Nottingham Prognostic Index (NPI) has a long history in clinical practice [4]. 
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Molecular tests are increasingly being used to provide information about prognosis to 
aid decision making about the possibility of omitting chemotherapy when low risk of 
distant DR is indicated [5]. Oncotype DX Breast Cancer Assay is such a molecular test, 
commercially provided from Genomic Health, Incorporated (GHI). It produces a 
Recurrence Score (RS) for the purpose of prognostication. In the England and Wales, in 
2013 it was recommended by the National Institute for Health and Care Excellence 
(NICE) for use in patients with ER+, human epidermal receptor-2-negative (HER2-) 
early advanced breast cancer, assessed on the basis of clinical algorithms to be at 
intermediate risk of DR and who would benefit from additional prognostic information 
to help guide chemotherapy prescribing [6]. It has been funded by NHS England for 
patients that have node-negative disease since 2015, and are judged by standard 
clinical and pathological criteria to be at intermediate risk of distant disease 
recurrence, and where the decision to prescribe chemotherapy remains unclear. 
Tang and colleagues have examined the information provided by RS combined with 
that derived from traditional clinicopathological features (tumour grade and size and 
patient age) standardised against endocrine treatment type (tamoxifen or aromatase 
inhibitor) [7]. Using data derived from node-negative patients entered into the 
tamoxifen-treatment arm of the National Surgical Adjuvant Breast and Bowel (NSABP) 
B-14 study [8], and the monotherapy-treatment arms of the translational research 
cohort in the Arimidex, Tamoxifen Alone or in Combination (TransATAC) study [9], they 
found that information contained in the two measures were complementary, and that 
combining them produced an indicator having substantially more prognostic power 
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than either set used singly: they termed this integrated risk estimate RS-pathology-
clinical (RSPC). RSPC risk estimates may be derived by means of a web-based tool 
provided for educational purposes by GHI, which is freely accessible to clinicians [10]. 
However, few oncologists use RSPC in patient management. 
Use of the Oncotype DX RS test is increasing in many countries, and is presently, 
standard practice in appropriate cases within most NHS clinical breast oncology units 
in England and Wales. We combined the data from four NHS Breast Units within the 
London region to compare risk estimates provided by RS and RSPC and to assess the 
relationship with RS-based clinical recommendations for chemotherapy use. 
MATERIALS AND METHODS 
Anonymised data (RS, patient age at surgery, tumour maximum diameter measured at 
resection, tumour grade, menopausal status, planned endocrine-based treatment 
type, and final clinical recommendation on addition of chemotherapy), were collected 
from four London NHS Foundation Trusts (Guy’s and St Thomas’, Royal Free London, 
The Royal Marsden and St George’s). Data were collected on patients having Oncotype 
DX tests ordered between January 2015 and September 2016 as part of routine clinical 
care in-line with NHS England agreed use in patients at intermediate risk of distant 
recurrence as assessed using NPI (score >3.40 and ≤5.40) or PREDICT (score ≥3% 
benefit). In the case of The Royal Marsden this was a consecutive series of all patients 
tested; for the other three centres, the patient series included only those where there 
was documented evidence of a clinical recommendation following receipt of the RS 
result. 
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The Oncotype DX breast cancer assay reports two measures related to recurrence risk: 
the RS itself, and an RS-derived percentage estimate of residual 10-year risk of distant 
DR assuming 5-years’ adjuvant endocrine treatment with tamoxifen, termed RS%. Both 
RS% and RSPC produce results on a 0-100% scale, and both use the same cut-points to 
define risk boundaries (vide infra), therefore to maximise comparability we report here 
on a comparison between RS% and RSPC. 
The published risk categories for RS were originally chosen based on results from the 
tamoxifen-treatment arm of the NSAPB B-20 trial [8], with scores less than 18 
designating low-risk, those between 18 and 30 intermediate-risk, and those above 30 
high-risk. On the basis of results from the NSAPB B-14 study, which was used to 
validate the assay, an RS of 18 equates to a 10-year residual risk of approximately 12% 
in a tamoxifen-treated population, while an RS of 31 is equivalent to a 21% risk. The 
same risk cut-points were designated for RSPC by Tang et al in their paper, and they 
have been retained here. 
RS% was calculated using tamoxifen as the intended endocrine treatment, which is in-
line with the default treatment for GHI-reported clinical cases. Tumour size and grade, 
patient age at surgery and intended endocrine treatment (tamoxifen or aromatase 
inhibitor) were combined with the RS to produce an RSPC. Web-based tools provided 
by GHI for were used to calculate the RS% and RSPC scores for each study case [10]. 
The NPI was calculated for each case using the published formula: 
NPI = [0.2 x S] + N + G 
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(where S is the size of the index lesion in centimetres, N is the node status [0 nodes = 
1, 1-4 nodes = 2, >4 nodes = 3], G is the grade of tumour [Grade I =1, Grade II =2, 
Grade III =3]) [11]. 
Correlation between RS% and RSPC scores was assessed using Spearman’s rho statistic. 
RS% and RSPC data were log-transformed prior to analysis. Agreement tables were 
constructed to compare the agreement of categorical assignments made by RS% and 
RSPC. RS% and RSPC derived categorical scores were correlated with chemotherapy 
recommendation. 
RESULTS 
Study cases 
A total of 177 cases from 174 patients having tumours tested by the Oncotype DX 
assay were submitted by the four hospitals’ breast units during the study period (3 
patients each had 2 concurrent assays performed on discrete tumours or tumour foci); 
6 cases (6 patients) were excluded from analysis, 1 due to node-positive status and 5 
due to missing RS result. Centre 3 contributed just under 55% of the cases, Centre 1 
approximately 20% and Centres 2 and 4 approximately 12% each. 171/177 cases 
(96.6%) from 168 patients (96.2%) were analysed for concordance.  
An additional 19 cases (19 patients) were excluded from analysis of treatment 
recommendation due to unavailable recommendation data, therefore 152 cases (149 
patients) were available. Supplementary Table S1 tabulates study and centre-specific 
case and patient numbers. 
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Median patient age at surgery was 53 years (range 24-78 years), with pre- and post-
menopausal women being almost equally represented (46.6% and 49.4% respectively). 
Patient demographics showed some centre-to-centre variation; the median age for 
women in Centre 1’s case-set was 49 years (range 33-74 years), noticeably lower than 
that for the study overall; at this centre, the proportion of pre-menopausal women 
was also higher (64.9%). This contrasts with Centre 3, where the median age of its 
patients was 56 years (range 24-78 years) and 40.4% were pre-menopausal. 
Almost all patients were node-negative (94.8%), in-line with NHS England referring 
guidance for the test. Seven patients (4.0%) presented with one or more micro-
metastasis and have been classified as node-negative. The single node-positive patient 
has been excluded. 
Median tumour diameter was 23mm (range 6-120mm), with the median diameter for 
cases from Centres 2, 3 and 4 all being closely similar to this; in contrast, tumours 
referred for testing at Centre 1 tended to be smaller, with a median tumour diameter 
of 18mm (range 6-70mm). 
Tumour grade distribution was closely similar for all centres, with the majority being 
Grade 2 (58.2%) or Grade 3 (40.1%), only Centre 3 tested any tumours that were Grade 
1 (1.1%). 
Median and range of NPI was closely similar for all centres. For the whole study the 
median was 4.0 (range, 2.4-5.4). Similarity in results for this index between centres 
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indicates that, although centre-specific differences existed in the distributions of 
tumour size and grade these characteristics were balanced for individual patients. 
Patient demographics and tumour characteristics together with information on NPI 
and treatment recommendations are shown in Table 1. 
RS% and RSPC scores 
Median 10-year DR risk estimate by RSPC was 15% (range 4%-63%); it was appreciably 
lower by RS% (11%, range 3%-34%) (Table 1). Correlation between RS% and RSPC was 
statistically significant (rho = 0.702, p<0.001, 2-tailed), with the rho value indicating 
that just under half of the variation seen in one measure could be explained by 
variation in the other. 
Agreement analysis for categorical assignment  
Cross-tabulation comparison demonstrated evidence for a considerable non-
concordance between RS%- and RSPC-based risk categorisations. The proportions of 
cases assigned respectively to each of the three risk categories by RS% and RSPC were 
markedly disparate. When RS% was used to classify cases 57.3% were designated as 
low-, 32.2% as intermediate-, and 10.5% as high-risk. When RSPC was used, the figures 
were, 33.9%, 35.7%, and 30.4%, respectively (see Chart 1 in Figure 1). 
Agreement was seen in a total of 99/171 cases (57.9%); 5 (2.9%) had a lower risk 
category classification and 67 (39.2%) a higher classification when RSPC rather than 
RS% was used. Comparing the categorical assignment of cases made by RS% and RSPC 
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in more detail; 32 (18.7%) classified as low-risk by RS% were increased by RSPC to 
intermediate-risk, and 12 (7.0%) to high-risk; 23 (13.5%) classified as intermediate-risk 
by RS% were increased to high-risk by RSPC. In contrast, decreased risk-classification of 
cases by RSPC compared to RS% was seen in only 5 cases, 4 (2.3%) decreased from 
intermediate-risk to low-risk, and 1 (0.6%) changed from high-risk to intermediate-risk 
(see Table 1 in Figure 1). 
Treatment recommendation 
Data on treatment recommendations were available on 149/174 patients (85.6%) 
(Table 2). Overall within the study, 96 patients (64.4%) were recommended to receive 
endocrine treatment alone, while there was a recommendation made for adding 
chemotherapy to endocrine-based treatment for 53 patients (35.6%). There were 
centre-specific differences seen in the proportions of patients receiving 
recommendations for the addition of chemotherapy; at Centre 1, the proportion of 
patients recommended to receive chemotherapy closely matched that of the whole 
study, while Centres 2 and 4 had similar proportion to each other, both of which were 
substantially lower than that in the whole study. In contrast, chemotherapy was 
recommended to a higher proportion of patients whose tests were conducted as part 
of their care pathway at Centre 3 (for details see Table 2). 
Stratified by RS%-designated risk-category, proportions of patients having a 
recommendation for the addition of chemotherapy were, 14/87 (16.1%) in the low-risk 
category, 27/49 (55.1%) in the intermediate-risk category, and 12/13 (92.3%) in the 
high-risk category. These results clearly indicate an association between RS% result 
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and treatment recommendation, and this association was recapitulated in the 
individual data from all centres (Table 2). 
A substantial number of patients with low-risk indications by RS% but RSPC risk scores 
indicative of intermediate- or high-risk received recommendations for adjuvant 
endocrine-based therapy alone. There was a total of 28 such patients (18.8%), 22 
(14.8%) with an intermediate-risk and 6 (4.0%) with a high-risk indication by RSPC. 
Such patients were present in the cohorts submitted by each centre (Table 3). 
DISCUSSION 
We report on a comparison between RS%, which is an RS-derived percentage estimate 
and RSPC, which incorporates clinicopathological parameters. Both produce results on 
a 0-100% scale, indicative of residual 10-year risk of distant DR assuming 5-years’ 
adjuvant endocrine treatment with tamoxifen using the same cut-points to define risk 
boundaries. 
In the study by Tang et al significant  improvement in prognostic performance was 
seen for RSPC over RS [7]. Similarly, RSPC had substantially improved prognostic 
performance when compared to clinicopathologic features alone. Here we show that 
there is a substantial upward shift in risk categorisation when RSPC rather than RS% 
score is applied to a contemporary cohort of patients. Considering the effect on 
treatment recommendations the most clinically relevant changes are those that cause 
37 patients (24.8%) to cross from low- to intermediate-risk, or, low- to high-risk. In this 
group 28 (75.7%) received an endocrine only recommendation, which they may not 
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have if the RSPC result had been used in place of RS%. Figure 2(c) shows a scatterplot 
relating all RS% and RSPC scores. In it most points clearly lie above the line of 
equivalence, indicating that, even when they do not cross risk boundaries the 
indicated risk of DR by is higher by RSPC compared to RS%. 
In patients where RSPC increased risk-category assignment, median tumour size was 
greater than for the whole study population (30mm versus 23mm) and seems to have 
been the main driver of the increase in risk estimation by RSPC since other 
demographic and clinicopathological parameters did not differ. Consequently, median 
NPI was also higher, at 4.3 versus 4.0. 
The trend for RSPC results within our series to indicate an increased risk of distant DR 
is in direct contrast with that seen by Tang et al in the NSABP B-14 and TransATAC 
cohorts, where the tendency was for RSPC results to classify fewer patients than RS as 
intermediate-risk (17.8% versus 26.7%) and more patients as lower risk (63.8% versus 
54.2%). This difference can be explained by the variances in the distributions of patient 
age, tumour size and most particularly tumour grade that exist in the populations 
examined by Tang et al and in our study. The median ages in the B-14, TransATAC and 
our study were 58, 63 and 53 years respectively, median tumour sizes were 20, 18 and 
23mm, the proportions of Grade 1 tumours were 35%, 22% and 1%, while those for 
Grade 3 tumours were 20%, 18% and 40%. All these measures indicate that the 
patients within our study represented a population at higher risk, this being an 
inevitable consequence of eligibility requirements set for the test by NHS England. 
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Limited evidence has been published indicating that patients with low Oncotype DX 
scores may gain little from chemotherapy even though their clinicopathological 
features may indicate they are at high-risk of recurrence [12,13]. However, central 
meta-analyses of chemotherapy (anthracycline- or taxane-based) trials in both ER+ and 
ER- breast cancer patients have produced little or no evidence for stratification of 
benefit according to clinicopathological features. Rather, they have shown that the 
benefit from chemotherapy is proportional to overall risk [14]. With the current 
discordant data, it is unknown if the superior prognostic performance of RSPC 
compared to RS would necessarily translate into improved prediction of benefit from 
chemotherapy. The data in this current study cannot address the relative predictive 
value of either score. In particular, it is cannot be known if patients who are converted 
from low risk RS to intermediate risk by RSPC, derive benefit from chemotherapy.  
The TAILORx prospective trial examining the use of Oncotype DX scores to stratify 
treatment in ER+ (and/or progesterone receptor-positive), HER2-, node-negative early 
advanced breast cancer has reported 5-year results on its low-risk patient cohort 
assigned to receive endocrine treatment alone [15]. In this group of 1626 patients the 
rate of freedom from DR was 99.3% (95% CI, 98.7 to 99.6). Potentially, this is very 
strong evidence for the effectiveness of the RS alone in assigning risk. However, the 
eligibility criteria for patients in TAILORx differ very substantially from those in our 
study; the RS cut-off defining low-risk was ≤10 not ≤17, tumours could be up to 50mm 
in diameter only if Grade 1, and ≤10mm if Grade 2 or 3. Examination of the data of size 
distribution for the study shows that the vast majority (92%) were less than 30mm. In 
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summary, this population’s clinicopathological profile is heavily weighted towards low-
risk, such that few (if any) would have a RSPC of >10%. 
Our evidence for the association between RS% and treatment recommendation relies 
on observed increasing proportions of patients with recommendations for 
chemotherapy usage in the three ascending RS%-assigned risk categories (16.1%, 
55.1%, 92.3% respectively). Clinical recommendations of this type do not rely on any 
single parameter alone, but on a synthesis of multiple observations about tumour 
biology, clinical presentation, patient co-morbidities and other factors and that the 
treating clinician and/or the multi-disciplinary team amalgamate to arrive at their final 
decision regarding treatment recommendations. Countering this is evidence presented 
in a recently published retrospective study conducted in the USA looking at 431 
patients who had their RS result integrated into a multivariable regression analysis 
together with clinicopathological features. The study found RS indicative of 
intermediate- or high-risk was the single most influential factor indicating likelihood of 
chemotherapy use [16]. 
Currently, Oncotype DX is the only molecular prognostic profiling tool recommended 
for use in the NHS in England and Wales, but elsewhere the availability of test is 
broader. For example American Society of Clinical Oncologists has recently endorsed 
the use of MammaPrint (agendia NV) for node-negative patients clinically indicated to 
be at high-risk [17]. 
There are some limitations to the study presented here and conclusions drawn from its 
analysis should be viewed with some caution. The sample size is relatively small 
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although the data were largely consistent between the 4 centres despite some 
differences on the characteristics of recruited patients. We have not been able to 
present any outcome data; to determine fully the clinical validity of the results patients 
would need to be randomised to management according to the 2 scoring methods. All 
prognostic indices that rely on assessment of clinicopathologic criteria such as grade 
are potentially subject to confounding intra-observer variability, and this may be a 
particular problem where strict adherence to standards is not in-place. The study’s 
patient population has been defined using NHS England criteria of node-negative and 
intermediate risk by NPI or similar, and this is not universally applicable to tested 
populations in other parts of the world. 
CONCLUSION 
In a clinically relevant patient population judged by standard clinical and pathological 
features to be at intermediate risk of disease recurrence, and in England and Wales as 
defined by NHS England guidelines for Oncotype DX use, RSPC indicates that 
substantially fewer patients are at low-risk and substantially more are at high-risk of 
DR when compared to RS%. Since RSPC produces a superior estimate of risk (but not 
necessarily of chemosensitivity) it presents a standard option to use in preference to 
the RS% when decisions about chemotherapy recommendation are being made on the 
basis of a patient’s risk of DR. The relatively small sample size and absence of outcome 
data indicate that conclusions should be viewed with some caution and require further 
validation by additional studies. 
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